首页> 外文期刊>Frontiers in Microbiology >A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library
【24h】

A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library

机译:药物组合筛选可从FDA药物库中鉴定出对阿莫西林诱导的体外疏螺旋体burgdorferi 持久性圆形体有活性的药物

获取原文
           

摘要

Although currently recommended antibiotics for Lyme disease such as doxycycline or amoxicillin cure the majority of the patients, about 10–20% of patients treated for Lyme disease may experience lingering symptoms including fatigue, pain, or joint and muscle aches. Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi , we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline. Eleven individual drugs scored better than metronidazole and tinidazole which have been previously described to be active against round bodies. In this amoxicillin-induced round body model, some drug candidates such as daptomycin and clofazimine also displayed enhanced activity which was similar to a previous screen against stationary phase B. burgdorferi persisters not exposure to amoxicillin. Additional candidate drugs active against round bodies identified include artemisinin, ciprofloxacin, nifuroxime, fosfomycin, chlortetracycline, sulfacetamide, sulfamethoxypyridazine and sulfathiozole. Two triple drug combinations had the highest activity against amoxicillin-induced round bodies and stationary phase B. burgdorferi persisters: artemisinin/cefoperazone/doxycycline and sulfachlorpyridazine/daptomycin/doxycycline. These findings confirm and extend previous findings that certain drug combinations have superior activity against B. burgdorferi persisters in vitro , even when pre-treated with amoxicillin. These findings may have implications for improved treatment of Lyme disease.
机译:尽管目前推荐的用于莱姆病的抗生素(例如强力霉素或阿莫西林)可以治愈大多数患者,但约10–20%接受莱姆病治疗的患者可能会出现挥之不去的症状,包括疲劳,疼痛或关节和肌肉疼痛。在饥饿或抗生素暴露等实验压力条件下,伯氏疏螺旋体会形成圆形体,这是一种持久性细菌,在体外对莱姆病的常规一线抗生素具有耐药性。为了鉴定对B. burgdorferi的圆形体具有活性的更有效药物,我们建立了通过暴露于阿莫西林(50μg/ ml)诱导的圆形体持久性模型,然后筛选了由1581种药物组成的食品药品监督管理局药品库以及使用SYBR Green I /碘化丙啶生存力分析的22种药物组合。我们确定了23种候选药物,它们对B. burgdorferi的圆形物体具有比阿莫西林或强力霉素高的活性。十一种药物的得分均高于甲硝唑和替硝唑,后者先前已被描述对圆形物体具有活性。在这种由阿莫西林诱导的圆形模型中,某些药物候选物(例如达托霉素和氯法齐明)也显示出增强的活性,类似于先前针对固定相B. burgdorferi坚持者未暴露于阿莫西林的筛选。鉴定出的对圆形物体有活性的其他候选药物包括青蒿素,环丙沙星,尼呋辛肟,磷霉素,金霉素,磺乙酰胺,磺胺甲氧哒嗪和磺胺噻唑。两种三联药物组合对阿莫西林诱导的圆形物体和固定期B. burgdorferi持久性具有最高活性:青蒿素/头孢哌酮/强力霉素和磺胺氯哒嗪/达托霉素/强力霉素。这些发现证实并扩展了先前的发现,即某些药物组合即使在用阿莫西林预处理的情况下,在体外对B. burgdorferi持久性药物也具有优异的活性。这些发现可能对改善莱姆病的治疗有影响。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号